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Health care delivery is increasingly evaluated according to quality measures, yet such 19 
measures are underdeveloped for cirrhosis. The Practice Metrics Committee of the 20 
American Association for the Study of Liver Diseases was charged with developing 21 
explicit process- and outcome-based measures for adults with cirrhosis. We identified 22 
candidate measures from comprehensive reviews of the literature and input from expert 23 
clinicians and patient focus groups. We conducted an 11-member expert clinician panel 24 
and used a modified Delphi method to systematically identify a set of quality measures 25 
in cirrhosis. Among 119 candidate measures, 46 were identified as important measures 26 
to define quality of cirrhosis care, including 26 process measures, 7 clinical outcome 27 
measures, and 13 patient-reported outcome measures. The final process measures 28 
captured care processes across the entire spectrum from diagnosis, treatment, and 29 
prevention for ascites (5 measures), varices/bleeding (7 measures), hepatic 30 
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liver transplantation evaluation (2 measures), and other care (7 measures). Clinical 1 
outcome measures included survival, variceal bleeding and re-bleeding, early-stage 2 
HCC, liver-related hospitalization, and rehospitalization within 7 and 30 days. Patient-3 
reported outcome measures covered physical symptoms, physical function, mental 4 
health, general function, cognition, social life, and satisfaction with care. The final list of 5 
patient-reported outcomes was validated in 79 cirrhosis patients from 9 institutions in 6 
the United States. 7 
Conclusion: We developed an explicit set of evidence-based quality measures for adult 8 
patients with cirrhosis. These measures are a tool for providers and institutions to 9 
evaluate their care quality, drive quality improvement, and deliver high-value cirrhosis 10 
care. The quality measures are intended to be applicable in any clinical care setting in 11 
which care for patients with cirrhosis is provided. 12 
BACKGROUND 13 
Cirrhosis is the final common pathway for all chronic liver diseases. Cirrhosis 14 
predisposes to a range of complications, including synthetic dysfunction, ascites, 15 
hepatic encephalopathy, variceal bleeding, and hepatocellular cancer (HCC). The 16 
prognosis of cirrhosis is highly variable. Patients with compensated disease may live 17 
with cirrhosis for a long time (median survival of 12 years1). However, survival in 18 
cirrhosis patients after hepatic decompensation or HCC is dismal (approximately 24 and 19 
8 months,2,3 respectively). Liver transplantation can be lifesaving in patients with 20 
cirrhosis; however, only a small minority undergo transplantation. Cirrhosis is also 21 
resource intensive. Most complications require hospitalization,4
 
and nearly 70% of 22 
patients are readmitted within 1 year, costing >$20,000 per admission.5 The burden of 23 
cirrhosis is amplified by its dramatic impact on quality of life resulting from multiple 24 
physical, psychological, cognitive, and social stressors.6
 26 
  25 
Many clinical practice guidelines that support evidence-based treatments for patients 27 
with cirrhosis exist.7-13 Despite these treatments, there are substantial shortfalls in the 28 
quality of cirrhosis care,14,15 suggesting a role for systematic quality improvement. 29 
Furthermore, the recent shift to value-based health care poses an urgent need to 30 
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4 
value of cirrhosis care is the lack of standardized measures for tracking quality within 1 
and across health care settings.  2 
 3 
To evaluate the quality of care, most quality improvement programs rely on multiple 4 
measures, including a combination of process and outcome measures.17
 14 
 A process-5 
based measure evaluates the extent to which health professionals, institutions, or health 6 
plans provide or achieve the element of care included in the measure (eg, HCC 7 
screening, varices prophylaxis). Process measures have the advantage of requiring less 8 
risk adjustment because properly constructed specifications narrowly define the clinical 9 
circumstances for indicated care. Outcome-based measures require risk adjustment but 10 
define the most critical outcomes in health and health care (eg, physical function, 11 
hospitalization, survival). In this context, “risk adjustment” means adjusting for non-12 
modifiable risk factors for poor outcomes. 13 
Identifying and implementing a standard set of process- and outcome-based measures 15 
for cirrhosis is an essential step in promoting value improvement in cirrhosis care. An 16 
explicit set of process measures for cirrhosis care was developed over 10 years ago.18 17 
Although these measures have been used to evaluate quality of cirrhosis care in 18 
disparate health care settings,14,15,19-21
 25 
 they do not reflect recent advances in cirrhosis 19 
management. Furthermore, there has been limited effort in developing outcome 20 
measures for patients with cirrhosis. The lack of well-defined outcome measures is a 21 
main roadblock in implementing value-based programs in cirrhosis, where value is 22 
defined as achieving desired outcomes relative to the cost of care for patients with 23 
cirrhosis.  24 
To fill these gaps, the American Association for the Study of Liver Diseases (AASLD) 26 
Practice Metrics Committee recently developed a standard set of quality measures, 27 
including process- and patient-centered outcomes for adults with cirrhosis. We aimed to 28 
select measures that, if implemented, would allow reliable and accurate measurement, 29 
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 1 
We used a predefined stepwise approach to identify the quality measures set as 2 
follows. A working group identified the candidate process and outcome measures based 3 
on a structured literature review and clinical experience. The working group then 4 
convened a separate 11-member expert panel that used 2-round modified Delphi 5 
method to identify the final measures set based on their importance, reach, and 6 
performance gap. These criteria were specified a priori and are described in detail in the 7 
section below. Patient focus groups and surveys were conducted to obtain patient input 8 
(Figure 1). We describe these steps in details below.  9 
AASLD Practice Metrics Committee working group 10 
The working group consisted of 10 AASLD Practice Metrics Committee members, 11 
including adult and pediatric hepatologists working in community and academic settings 12 
across the United States; several members also had specific expertise in health 13 
services research and epidemiology. The working group worked closely with 2 patient 14 
representatives (1 patient with decompensated liver disease and 1 caregiver) to ensure 15 
that outcomes perceived as important by patients were included in the candidate list.  16 
Identification of the candidate measures set 17 
The working group convened via conference calls between January and October 2017, 18 
with 1 face-to-face meeting in September 2017.  19 
 20 
The working group defined the scope of the measures set to include all adult patients 21 
with cirrhosis regardless of the type and severity of complications, with few exceptions. 22 
The group purposely excluded processes and outcomes of care related to treatment of 23 
HCC because it is highly specialized and requires combined efforts from multiple 24 
disciplines. Moreover, the target population with HCC might be heterogeneous in terms 25 
of the severity of underlying liver disease, stage of tumor, and functional status to allow 26 
reliable quality measurement. Similarly, we excluded the processes and outcomes of 27 
care that occur immediately before or after transplantation (pre-transplantation 28 
evaluation, transplant procedure, post-transplant immunosuppressant use, etc.) 29 
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 1 
For process-based measures, the group started with a published process measures 2 
set.18
 6 
 The working group reviewed clinical practice guidelines published since 3 
development of the previous set to identify additional process measures to be included 4 
in the candidate measure list. 5 
The group recognized that patient-centered outcome measurement in cirrhosis needs to 7 
encompass disease complications, hospitalization, and survival (clinical outcomes) as 8 
well as measures capturing patients’ own assessment of their health status, including 9 
symptoms and physical, social, and mental functioning (patient-reported outcomes).22 10 
The working group performed a scoping review of literature to identify a comprehensive 11 
set of patient-reported outcomes for inclusion into the candidate measures. The results 12 
of this review are published elsewhere.6
 16 
 The working group then reviewed the list of 13 
candidate outcome measure and identified additional outcomes that captured the 14 
clinical status of patients with cirrhosis.  15 
To ensure that we included patients’ perspective in the outcomes identification, 2 17 
separate focus groups of patients with cirrhosis and their caregivers were conducted in 18 
August 2017 (guided by MV). These included 7 patients on the liver transplant list and 7 19 
caregivers. The discussion was guided by a semistructured format and continued until 20 
thematic saturation was reached.23
Modified 2-round Delphi process 25 
 Saturation is a widely accepted methodological 21 
principle in qualitative research. Thematic saturation occurs when new data (eg, 22 
comments, themes) become redundant with data already collected, indicating that 23 
further data collection is unlikely to yield additional information.  24 
We used a modified Delphi approach to identify a set of cirrhosis quality measures.24 26 
This is a formal group method in which an expert panel discusses and iteratively rates 27 
candidate quality measures by using a 2-round process. In the first round, the experts 28 
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the second round—a face-to-face meeting—their preliminary ratings for the measures 1 
were discussed and then re-rated through an equally weighted voting.  2 
 3 
Expert panel. A group of 11 hepatologists with content expertise participated in the 4 
modified Delphi process (see Acknowledgments section for names and affiliations of the 5 
panel members). We selected the panel members based on their recent publications 6 
and participation in the Advisory Councils for professional societies. The selection 7 
process was designed to maintain the geographic, clinical practice, and research 8 
interest diversity among the group.  9 
Pre-meeting ratings (round 1). We instructed the panel to rate each measure on the 10 
following 3 criteria on a 9-point Likert scale: importance (primary criterion), reach, and 11 
performance gap. We defined a process measure to be “important” if (a) strong 12 
scientific evidence exists demonstrating that compliance with a given process of care 13 
improves health care outcomes, (b) the process being measured is closely connected to 14 
the outcome it impacts, and (c) the magnitude of effect of performing the measure is 15 
large enough that it is worth doing. We defined an outcome to be important if it (a) is 16 
important to patients or clinicians, (b) is meaningful across multiple populations, and (c) 17 
can help facilitate change and quality improvement. The importance scale ranged from 18 
1 (“not important at all”) to 9 (“extremely important”) where 1-3 indicated “definitely not 19 
important,” 4-6 indicated “uncertain or equivocal importance,” and 7-9 indicated 20 
“definitely important.” The “reach” of a measure was defined as the number of patients it 21 
applies to, where 1 indicated “smallest reach: applicable to few or no patients” and 9 22 
indicated “largest reach: applicable to almost all patients.” “Performance gap” was 23 
defined as the gap between current and desired performance on each process measure 24 
or gap between current and desired level for each outcome from 1 (no gap) to 9 (largest 25 
gap).  26 
We determined the median panel rating and a measure of agreement for each measure 27 
for each criterion. Based on a priori considerations, we relied on ratings of importance 28 
as the primary criterion to guide measure selection process. Specifically, we selected 29 
















This article is protected by copyright. All rights reserved 
8 
variation in expert ratings.18,24 These selection criteria have been widely used to develop 1 
performance measures across several areas of medicine.25-29
 5 
 We defined no extreme 2 
variation when >80% of ratings were in the 7-9 range with none in the extreme 1-3 3 
range. 4 
Face-to-face meeting (round 2). The panel face-to-face meeting was moderated by 6 
FK and MV (nonvoting members). During this half-day meeting, each panelist received 7 
a table comparing their scores with the median scores (generated by other panelists) for 8 
each measure. Discussion focused on the areas of disagreement to understand the 9 
sources of variation. Panel members were also tasked with identifying additional 10 
measures not on the original list, modifying existing measures that were imperfectly 11 
worded, and deleting measures that were perceived to be problematic or irrelevant. 12 
After an updated list of measures was developed, the panelists re-rated the importance, 13 
reach, and performance gap of each measure again by using the 9-point scale. We 14 
selected measures based on ratings of importance. As above, we considered a 15 
measure important if the median rating was 7-9 without any disagreement between the 16 
raters. We presented median ratings on the remaining 2 constructs for the final measure 17 
set.  18 
Validation of patient-reported outcomes 19 
The final list of patient-reported outcomes was reviewed by 79 cirrhosis patients from 20 
hepatology clinics at 9 institutions in the United States. Participants were asked to 21 
complete an anonymous survey, rating the importance of each outcome on a 4-point 22 
scale (not important, somewhat important, very important, and extremely important) with 23 
an option to include additional outcomes in text form.  24 
 25 
RESULTS  26 
Candidate measures  27 
The working group proposed 84 candidate measures, and the expert panel members 28 
recommended an additional 35 new measures. Among the set of 119 candidate 29 
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measures included care processes across the entire spectrum of care (diagnosis, 1 
treatment, and prevention) for ascites, varices, hepatic encephalopathy, HCC 2 
screening, liver transplantation evaluation, and general care. Of the 56 candidate 3 
outcome measures, 23 captured clinical (traditional) outcomes such as survival, 4 
hospitalization, and complications of cirrhosis. The remaining 33 were patient-reported 5 
outcome measures, covering 7 domains: physical symptoms, physical function, mental 6 
health, general function, cognition, social life, and satisfaction with care. See 7 
Supplementary Table 1 for the full list of candidate measures.  8 
Measures selected based on modified Delphi process 9 
Of the 119 candidate measures, 82 had a median rating of 7 or higher (Supplementary 10 
Table 1). Of these, we excluded 28 measures that met our definition of disagreement, 11 
as detailed above. Where appropriate, we combined selected measures based on 12 
content overlap to produce a final list of 46 measures. For example, experts rated use of 13 
intravenous albumin and use of antibiotics as important for patients with spontaneous 14 
bacterial peritonitis. We combined these 2 processes in 1 measure because both are 15 
recommended to be administered together in the management of spontaneous bacterial 16 
peritonitis. Similarly, we combined measures about diuretic use and dietary counseling 17 
regarding sodium intake in management of symptomatic ascites.  18 
 19 
Table 1 includes the final process measures set with corresponding median ratings of 20 
importance, reach, and gap. Of the final set, 26 were process measures; 5 covered 21 
ascites care, 7 variceal bleeding-related care, 4 hepatic encephalopathy, 1 HCC 22 
screening, and 2 liver transplantation evaluation, and the remaining addressed general 23 
care of patients with cirrhosis. The final measure set also included 7 clinical and 13 24 
patient-reported outcomes that were deemed important measures of quality of cirrhosis 25 
care by the expert panel (Table 2).  26 
Validation of patient-reported outcomes 27 
In total, 79 patients from 9 institutions completed a paper-based survey to rate the 28 
importance of patient-reported outcomes selected as part of the modified Delphi 29 
process above. Patients represented a broad spectrum of disease severity, including 30 
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of these outcome measures. Over 80% of patients rated all outcome measures as 1 
“somewhat” to “extremely” important except for the alcohol abstinence outcome, which 2 
had a marked bimodal distribution. Patient-reported outcomes that were deemed “very 3 
or extremely” important by 80% or more patients included reducing abdominal fluid 4 
accumulation (ascites), improving concentration and memory, and reducing medication 5 
side effects.  6 
Measures by patient subgroups 7 
We grouped the final measures based on the types of cirrhosis patients they apply to. 8 
Supplementary Table 2 displays the final set of measures applicable to most patients 9 
with cirrhosis as well as those applicable to specific subgroups of cirrhosis patients.  10 
 11 
Measures applicable to most patients with cirrhosis. In total, 5 process, 2 clinical, 12 
and 8 patient-reported outcomes measures can be used to assess quality of care for 13 
most patients with cirrhosis, regardless of the specific clinical complication or stage of 14 
disease (Supplementary Table 2). The process measures include endoscopy for 15 
variceal screening, HCC screening, hepatitis B vaccination, frailty assessment, and 16 
management of patients with excessive alcohol use. Most of these measures were felt 17 
to have broad reach (median reach scores 8 to 9) with substantial gaps in current care 18 
(see Table 1).  19 
 20 
Patient survival was felt to be the most important clinical outcome measure, followed by 21 
liver-related hospitalization. Patient-reported outcomes, each with broad reach and 22 
applicability (median reach score >7) included control of cirrhosis symptoms (pruritus, 23 
muscle cramps), falls, medication side effects, burden on caregivers, depression, 24 
stigma, and alcohol abstinence. Experts felt that there were moderate gaps between the 25 
current and ideal clinical and patient-reported outcomes.  26 
 27 
Measures applicable to patients with ascites. There were 5 process measures and 2 28 
patient-reported outcomes that were deemed important measures of quality of ascites 29 
care (Supplementary Table 2). The reach of specific measures ranged from 3 30 
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(applicable to some but not all patients) for diagnostic paracentesis in hospitalized 1 
patients. The outcome measures included patient self-report of fluid accumulation 2 
(abdominal and overall). Experts felt that there were moderate gaps in the current and 3 
ideal clinical and patient-reported outcomes. 4 
 5 
Measures applicable to patients with varices/variceal bleeding. In total, 7 6 
processes and 2 clinical outcomes were considered important for measuring 7 
varices/variceal bleeding-related care. These included screening for varices, primary 8 
(and secondary) prophylaxis for variceal bleeding, and urgent endoscopy and 9 
appropriate therapy for patients with suspected acute variceal bleeding. Two clinical 10 
outcomes included first variceal bleeding and development of re-bleeding among 11 
patients with prior history of variceal bleeding. The reach of specific measures varied 12 
from 4 (for treatment of variceal bleeding) to 8 (for prevention of first episode of variceal 13 
bleeding). There were perceived moderate gaps in the current and ideal performance 14 
on process and clinical outcomes for variceal bleeding (see Table 1). 15 
 16 
Measures applicable to patients with hepatic encephalopathy. There were 4 17 
process measures and 3 patient-reported outcomes that were deemed important 18 
measures of quality of hepatic encephalopathy care (Supplementary Table 2). The 19 
process measures included counseling patients with prior overt hepatic encephalopathy 20 
about the risks associated with driving, searching for evidence of precipitating factors 21 
and treatment with lactulose in hospitalized patients with acute episodes of overt 22 
hepatic encephalopathy, and secondary prophylaxis with lactulose and/or rifaximin after 23 
resolution of acute episode. Patient-reported outcomes included self-reported episodes 24 
of confusion, impaired concentration and memory, and concern about inability to drive. 25 
The reach of process measures was felt to be low to moderate. In contrast, patient-26 
reported outcomes were deemed applicable to a larger subgroup of patients with 27 
cirrhosis, with median reach scores in the 7 to 8 range (Table 1). Experts felt that there 28 
were moderate gaps in the current and ideal clinical and patient-reported outcomes for 29 
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12 
Measures applicable to patients with HCC. The final set included 2 measures that 1 
can be used to assess quality of care for patients with HCC (Table 1). These included 1 2 
process measure (consideration of liver transplantation for patients with HCC meeting 3 
transplant criteria) and 1 outcome measure (early-stage HCC at the time of diagnosis). 4 
Both measures had moderate reach with moderate gaps between current and ideal 5 
performance. 6 
 7 
Other subgroups. Several measures were applicable to specific subgroups of cirrhosis 8 
patients, including patients who were hospitalized with cirrhosis (Supplementary Table 9 




We systematically developed a quality assessment tool that consists of 46 explicit 14 
measures, including both process measures as well as outcome measures relevant to 15 
the care of patients with cirrhosis. This effort is the first to identify an agreed upon set of 16 
outcome-based measures, including clinical and patient-reported outcomes in cirrhosis. 17 
Our development method, ie, the comprehensive literature review, the rigorous nature 18 
of the modified Delphi expert panel process, and extensive patient input, confers 19 
content validity on the selected measures.  20 
 21 
We believe that the measures included in the cirrhosis set will provide a means of 22 
evaluating the quality of cirrhosis care in a reproducible manner across different 23 
practitioners, settings, and institutions. This comprehensive quality assessment tool 24 
spans the spectrum of disease severity and includes several process- and outcome-25 
based measures for different cirrhosis complications, thereby allowing reliable 26 
assessment of quality of cirrhosis care. We also present data on potential reach of the 27 
measures as well as perceived gaps in the current quality. Collectively, this information 28 
can guide practitioners in selecting a subset that best fits their clinical context and 29 
quality improvement targets. For example, practices serving compensated patients with 30 
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most patients with cirrhosis, such as HCC screening, peripheral edema, and survival. In 1 
contrast, liver specialty clinics that primarily focus on patients with decompensated 2 
cirrhosis may select complication-specific measures (eg, ascites, hepatic 3 
encephalopathy, and varices-specific measures). Thus, although the full set (Tables 1 4 
and 2) provides health care professionals and institutions with a comprehensive quality 5 
assessment tool, we anticipate that individuals and institutions may select the measures 6 
that best fit their clinical context and quality goals.  7 
 8 
We recognize that a major barrier to implementing measures in clinical practice is the 9 
challenge of collecting data to successfully track and record performance. Successful 10 
implementation of these measures will require adaptations in technical infrastructure to 11 
allow data collection. Major electronic medical record vendors are creating structured 12 
data fields within specialty-specific templates that can allow collection of structured data 13 
for consistent and reliable quality assessments. Similarly, several tools exist that 14 
support collection and integration of patient-reported data into electronic health records. 15 
Future research is needed to determine whether patient surveys can be included and/or 16 
imported seamlessly into the electronic charts as discrete fields for easy abstraction. 17 
We recognize that, in addition to significant modifications in technical infrastructure, 18 
successful implementation of the standard set will require a significant change in clinical 19 
attitudes and workflow. Our near-term goal is to implement selected measures as part 20 
of the Cirrhosis Quality Collaborative initiative. In this step, we will include specification 21 
of case-mix factors as well as exclusion criteria for all measures to adjust for differences 22 
between theoretical guidelines and real care practice and to set benchmark 23 
performance in cirrhosis. In addition to improving the accuracy of measure, accounting 24 
for patient exclusion criteria and case-mix will allow comparisons across health care 25 
facilities with different patient populations. We will also develop procedures for 26 
implementation and sustainability of data collection—information that will pave the way 27 
for broader dissemination and adoption.  28 
 29 
We focused on measures that are intended for quality improvement efforts. We believe 30 
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without further research. Specifically, implementation of these measures for 1 
accountability, in contrast with quality improvement efforts, will require further testing to 2 
address a variety of issues pertaining to the identification of a subset that not only is 3 
important but also meets the criteria for necessary care (ie, the expected benefits not 4 
only outweigh the expected harms, but they do so by such a margin that the provider 5 
must offer the service); other issues include methods of data collection, frequency of 6 
implementation, comparability among practices, audit requirements, the system of 7 
public reporting, and more importantly, the input from stakeholder groups, including 8 
third-party payers and policy makers. Future work of the Practice Metrics Committee will 9 
evaluate whether some of the measures in the cirrhosis set can be applied for tracking 10 
quality for purposes of accountability in cirrhosis.  11 
 12 
Though we are confident that we captured critical processes and outcomes, we also 13 
recognize that our measurement set does not encompass all measures that may matter 14 
to patients with cirrhosis. Several measures were underrepresented because of 15 
limitations related to the quality and quantity of data supporting the measures. For 16 
example, although screening for minimal hepatic encephalopathy may be important, 17 
available tests lack specificity for the condition.30 Several measures were not included in 18 
the candidate list due to difficulty in defining the target condition (such as refractory 19 
ascites, refractory variceal bleeding, and stage III/IV hepatic encephalopathy) using 20 
readily available data. These conditions would require manual chart reviews to define 21 
and might not be feasible in quality improvement efforts that require repeated 22 
assessments.31
 28 
 Some measures (such as screening for harmful alcohol use and clinical 23 
depression) were not specifically addressed because these measures are applicable to 24 
all patients seeking health care and are already included in several quality-reporting and 25 
payment programs sponsored by commercial payers and government agencies (eg, 26 
Medicare’s quality reporting Merit-based Incentive Payment System).  27 
In summary, we have developed an explicit set of 46 evidence-based measures 29 
relevant to several aspects of care in adults with cirrhosis. The measures may provide 30 
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15 
quality improvement interventions. The outcome measures included in the final set will 1 
be important as we adapt to evolving health care delivery models that attempt to 2 
optimize quality of care. The measures are intended to be applicable in different health 3 
care settings in which care for patients with cirrhosis is provided.  4 
 5 
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Figure 1 Legend 13 
 14 
Steps in the development of cirrhosis quality measures set. We identified candidate 15 
measures from published set of process measures, a scoping review of the literature, 16 
and input from expert clinicians as well as patient focus groups. Using the modified 17 
Delphi method, an expert panel of clinicians voted on the candidate measures to 18 
systematically identify a set of quality measures in cirrhosis. The final list of patient-19 
reported outcomes was reviewed and endorsed by cirrhosis patients from 9 institutions. 20 
 21 
 Table 1. Process Measures 
 
Median  
 Process Measures Importance Reach Gap 
1 Patients with ascites who are admitted to the hospital for evaluation and 
management of symptoms related to ascites or encephalopathy should 
receive a diagnostic paracentesis during the index hospitalization 
9 7 6 
2 Patients who are admitted with or develop GI bleeding should receive 
antibiotics within 24 hours of admission or presentation. Antibiotics 
should be continued for at least 5 days 
9 4 5 
3 Patients undergoing large-volume paracentesis (>5 liters removed) 
should receive intravenous albumin (6-8 grams per liter removed) 
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4 Hospitalized patients with ascites, with an ascitic fluid 
polymorphonuclear count of ≥250 cells/mm3
8 
, should receive empiric 
antibiotics and albumin within 12 hours of the test result. The first dose of 
albumin should be 1.5 g per kg body weight followed by a second 
infusion of 1.0 g/kg on day 3. 
3 6 
5 Patients with ascites and/or hepatic hydrothorax should be managed 
with both sodium restriction and diuretics. 
8 3 4 
6 Patients who undergo paracentesis should not receive fresh frozen 
plasma or platelets 
8 5 7 
7 Patients with cirrhosis, with platelet count <150,000/mm
3
8  or liver stiffness 
measurement >20 kPa, and no documentation of previous GI bleeding, 
should receive upper endoscopy to screen for varices within 12 months 
of cirrhosis diagnosis  
6 5 
8 Patients with decompensated cirrhosis and no documented history of 
previous GI bleeding should receive upper endoscopy to screen for 
varices within 3 months of cirrhosis diagnosis 
8 4 5 
9 Patients with cirrhosis, no documented history of previous GI bleeding, 
and medium/large varices on endoscopy should receive either 
nonselective β-blockers or EVL within 1 month of varices diagnosis. 
8 5 4 
10 Patients with cirrhosis who present with upper GI bleeding should 
receive upper endoscopy within 12 hours of presentation 
9 5 5 
11 Patients with cirrhosis who are found to have bleeding esophageal 





12 Patients with cirrhosis who survive an episode of acute variceal 
hemorrhage should receive a combination of EVL and β-blockers. 
8 4 5 
13 Patients with prior overt hepatic encephalopathy should be counseled 
regarding the risks associated with driving. 
8 4 7 
14 Patients with hepatic encephalopathy should have a search for evidence 
of precipitating factors documented in the chart. 
8 4 6 
15 Patients who are hospitalized and have an acute episode of overt 
hepatic encephalopathy should receive lactulose. 
8 4 4 
16 Patients who are discharged after an acute episode of hepatic 
encephalopathy should receive secondary prophylaxis with lactulose 
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and/or rifaximin  
17 Patients with cirrhosis and MELD score ≥15 who do not have absolute 
contraindications to liver transplantation should have documentation of 
evaluation for liver transplantation. 
8 5 7 
18 Patients with cirrhosis who do not have absolute contraindications to 
liver transplantation and have HCC meeting the transplant criteria should 
be considered for liver transplantation, irrespective of their MELD score. 
8 5 7 
19 Patients with cirrhosis should undergo HCC screening using abdominal 
imaging with or without serum α-fetoprotein every 6-12 months 
9 8 8 
20 Patients with cirrhosis should have hepatitis B immune status and/or 
vaccination documented in the chart. 
8 9 6 
21 Patients with untreated hepatitis C cirrhosis should be considered for 
antiviral therapy for hepatitis C 
9 6 5 
22 Patients with untreated hepatitis B cirrhosis should be considered for 
antiviral therapy for hepatitis B 
9 4 5 
23 Patients with cirrhosis should receive counseling or be referred to a 
substance abuse treatment program within 2 months of positive 
screening. 
9 8 6 
24 Patients with cirrhosis who are undergoing abdominal surgery should 
have documentation of the risk–benefit of undergoing the surgical 
procedure in the medical record 
8 7 7 
25 Recently discharged patients with cirrhosis should have a clinic visit with 
a health care provider within 4 weeks of discharge. 
8 5 7 
26 Patients with cirrhosis should be assessed for frailty using a systematic 
screening method 
8 7 7.5 
Abbreviations: EVL, endoscopic variceal ligation; GI, gastrointestinal; HCC, hepatocellular carcinoma; 1 
MELD, Model for End-Stage Liver Disease. 2 
 3 
Table 2. Outcome Measures 
Clinical Outcomes Importance Reach Gap 
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2 First variceal bleeding 8 8 6 
3 Variceal re-bleeding among patients with history of variceal bleeding 8 4 5 
4 Patients diagnosed at an early stage among patients with HCC 8 7 6 
5 Liver-related hospitalization  8 8 6 
6 Rehospitalization within 7 days 8 5 6 
7 Rehospitalization within 30 days 8 6 6 
Patient-Reported Outcomes  
8 Fluid in the legs (edema) 7 6 5 
9 Fluid in the belly (ascites) 8 4 6 
10 Confusion 8 8 6 
11 Concentration and memory 8 7 6 
12 Itching 8 3 6 
13 Muscle cramps 7.5 6 5 
14 Falls 7 6 5 
15 Medication side effects 7 7 5 
16 Depression 8 7 8 
17 Stigma of having liver disease 7 7 6 
18 Ability to drive  8 6 7 
19 Burden on family 8 7 7 
20 Be able to avoid alcohol 8 6 6 

















This article is protected by copyright. All rights reserved 
22 
Table 3. Patient Ratings of Patient-Reported Outcomes (%) 





Fluid in the legs (edema) 8.9% 14.1% 76.9% 
Fluid in the belly (ascites) 3.8% 5.1% 91.1% 
Confusion (encephalopathy) 1.3% 10.1% 88.6% 
Concentration/memory 6.4% 16.7% 76.9% 
Itching (pruritus) 5.2% 12.9% 81.8% 
Muscle cramps 12.9% 36.4% 50.7% 
Falls 12.8% 17.9% 69.2% 
Medication side effects 8.9% 17.9% 73.1% 
Depression 7.6% 21.7% 70.5% 
Stigma of having liver disease 5.1% 14.1% 80.8% 
Ability to drive 10.1% 22.8% 67.1% 
Burden on family 35.1% 5.2% 59.8% 
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